Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.
The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.
Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Amer M
AM
Zeidan
Ju-Whei
JW
Lee
Thomas
T
Prebet
Peter
P
Greenberg
Zhuoxin
Z
Sun
Mark
M
Juckett
Mitchell R
MR
Smith
Elisabeth
E
Paietta
Janice
J
Gabrilove
Harry P
HP
Erba
Martin S
MS
Tallman
Steven D
SD
Gore
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*; D011379:Prognosis; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D056572:Histone Deacetylase Inhibitors; D001374:Azacitidine
French Prognostic Scoring System; azacitidine; myelodysplastic syndromes; prognostic models; revised International Prognostic Scoring System